Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yao Jiang


Postdoctoral Researcher

I graduated from Peking University with a B.Sc. degree in Pharmaceutical Sciences before moving to the Peking Union Medical College, Chinese Academy of Medical Sciences to carry on my PhD. My PhD project was focused on targeting drug delivery system construction for cancer therapy where I found a novel peptide for targeting non-small cell lung cancer. After my PhD, I joined the University of Birmingham as a research fellow and start working on a project to investigate new treatments for cancer by drug redeployment research to provide affordable therapies that can be exploited by all including the worlds poorer nations. Our finding suggested a triple-drug combination could form an effective and non-toxic treatment for a range of aggressive blood cancers. This study has led to a clinical trial in 2021 (NCT04997811).

I joined the University of Oxford in 2022 as a postdoctoral researcher on tumour biology working in Kerr/Cai group.

Other activities

Guest editor

Frontiers in Molecular Biosciences


Peer Reviewer

International Journal of Molecular Sciences

Molecular pharmaceutics

Key publications

Recent publications

More publications